Results 91 to 100 of about 17,227 (165)

No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients

, 2002
Objective: This aim of this study was to compare the pharmacokinetics of topotecan in the presence and absence of preceding amifostine to reduce the risk of side effects in patients with advanced ovarian cancer.
Zackrisson, Anna-Lena, Malmström, Henric,, Peterson, Curt   +2 more
core   +1 more source

Effective Dosing of Topotecan With Carboplatin in Relapsed Ovarian Cancer: A Phase I/II Study

, 2001
PURPOSE: This phase I/II study was performed to evaluate the feasibility of administering the topoisomerase inhibitor topotecan in combination with carboplatin.
A. Bowman, G. Ross, T. Rye, A. Wheatley, J. F. Smyth   +4 more
core   +1 more source

Topotecan in second-line therapy of SCLC: Impact on survival? [PDF]

, 2000
Kleinschmidt, R., Hruska, D., Mezger, J., Pawel, J. von, Saal, J. G., Gatzemeier, U., Steppling, H., Huber, Rudolf M., Gosse, H., Steppert, C., R. Kleinschmidt, H. Steppling, H. Gosse, R.M. Huber, J. von Pawel, J.G. Saal, D. Hruska, U. Gatzemeier, J. Mezger, C. Steppert   +19 more
core   +1 more source

Voltammetric Studies of Topotecan Transfer Across Liquid/Liquid Interfaces and Sensing Applications

, 2015
An amperometric ion sensor featuring a microhole supported water/organic gel interface was developed for the quantitative analysis of a water-soluble anticancer drug species, namely, topotecan, which has been used for ovarian and lung cancer treatments ...
Carlos M. Pereira (1598554), Hye Rim Kim (225882), Hye Jin Lee (67018), Hye Youn Han (1598551)   +3 more
core   +1 more source

Topotecan in platinum-resistant epithelial ovarian cancer

, 2005
Background: Topotecan has been emerged as a new promising anticancer drug for patients with ovarian cancer. Methods: In this study, patients who were treated with topotecan were reviewed retrospectively. A total of 26 patients was included the study. All
Dikmen Y., Akman L., Uslu R., Terek M.C., Goker E., Karabulut B., Sezgin C., Ozsaran A., Sanli U.A.   +8 more
core   +1 more source

Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2010
Background and objective How to prolong progression free survival (PFS) and overall survival (OS) of patients with small cell lung cancer (SCLC) has been one of the hottest issues. We retrospectively reviewed our data to compare the survival of immediate
Cong XUE, Yuanyuan ZHAO, Liping LIN, Guangchuan XU, Hongyun ZHAO, Yang ZHANG, Wei JIANG, Li ZHANG   +7 more
doaj  

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

, 1996
PURPOSE To determine the maximum-tolerated systemic exposure (MTSE) and exposure-limiting toxicity of continuous infusion topotecan in children with recurrent acute leukemia.
W E Evans, C B Pratt, S D Baker, W L Furman, C F Stewart, G K Rivera   +5 more
core   +1 more source

Phase I and pharmacologic study of topotecan in patients with impaired renal function.

, 1996
PURPOSE To determine the toxicities, pharmacokinetics, and recommended doses of the topoisomerase I inhibitor, topotecan, in patients with varying degrees of renal excretory dysfunction.
A A Forastiere, S O'Reilly, T L Chen, L B Grochow, D S Ettinger, S Sartorius, E K Rowinsky, W Slichenmyer, R C Donehower   +8 more
core   +1 more source

Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway

, 2018
Mohammad Hassan Hodroj, Achraf Jardaly, Sarah Abi Raad, Annalise Zouein, Sandra Rizk Department of Natural Sciences, Lebanese American University, Beirut, Lebanon Background: Topotecan (TP) is an anticancer drug acting as topoisomerase I inhibitor that ...
Abi Raad S, Rizk S, Jardaly A, Hodroj MH, Zouein A   +4 more
core  

Intra-arterial chemotherapy for retinoblastoma: a structured narrative review. [PDF]

World J Pediatr Surg
Ren YH, Kang D, Shi C, Sun W.
europepmc   +1 more source